Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.

IF 3.4 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-09-13 DOI:10.3390/curroncol32090510

Ahmet Oruç, Mustafa Erol, Özlem Şahin, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç

{"title":"Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.","authors":"Ahmet Oruç, Mustafa Erol, Özlem Şahin, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç","doi":"10.3390/curroncol32090510","DOIUrl":null,"url":null,"abstract":"Purpose: This study aims to determine whether body composition parameters affect progression-free survival (PFS) in patients with hormone receptor positive and HER-2 negative metastatic breast cancer treated with ribociclib as first-line therapy.Materials and methods: It was designed as a single-center, retrospective study; therefore, its generalizability is limited. At the start of treatment, 18F-FDG PET/CT scans were performed on patients, and subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volume, SAT and VAT SUV (standardized uptake value) mean, SAT and VAT index, skeletal muscle index (SMI), and skeletal muscle radiodensity (SMD) were calculated at the L3 vertebra level. The albumin-myosteatosis gauge (AMG) was defined as SMD × albumin.Results: The study included 73 participants. Increased SAT and VAT volumes were associated with worse PFS (23.4 vs. 35.5 months, p: 0.015; 25.4 vs. 33.3 months, p: 0.114). However, in the multivariable cox regression analysis for progression free survival (PFS), an increase in SAT volume [HR 4.96; p: 0.038)] and SAT SUV mean [HR 2.99; p: 0.016)] were identified as independent risk factors.Conclusions: It should be noted that in patients treated with ribociclib, increases in SAT volume and SAT SUV mean are independent risk factors for PFS.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468890/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32090510","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aims to determine whether body composition parameters affect progression-free survival (PFS) in patients with hormone receptor positive and HER-2 negative metastatic breast cancer treated with ribociclib as first-line therapy.

Materials and methods: It was designed as a single-center, retrospective study; therefore, its generalizability is limited. At the start of treatment, ¹⁸F-FDG PET/CT scans were performed on patients, and subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volume, SAT and VAT SUV (standardized uptake value) mean, SAT and VAT index, skeletal muscle index (SMI), and skeletal muscle radiodensity (SMD) were calculated at the L3 vertebra level. The albumin-myosteatosis gauge (AMG) was defined as SMD × albumin.

Results: The study included 73 participants. Increased SAT and VAT volumes were associated with worse PFS (23.4 vs. 35.5 months, p: 0.015; 25.4 vs. 33.3 months, p: 0.114). However, in the multivariable cox regression analysis for progression free survival (PFS), an increase in SAT volume [HR 4.96; p: 0.038)] and SAT SUV mean [HR 2.99; p: 0.016)] were identified as independent risk factors.

Conclusions: It should be noted that in patients treated with ribociclib, increases in SAT volume and SAT SUV mean are independent risk factors for PFS.

查看原文本刊更多论文

体成分对接受核波西尼治疗的转移性乳腺癌患者无进展生存期的影响。

目的：本研究旨在确定体成分参数是否影响激素受体阳性和HER-2阴性转移性乳腺癌患者的无进展生存期（PFS）。材料和方法：设计为单中心回顾性研究；因此，其通用性是有限的。治疗开始时，对患者进行18F-FDG PET/CT扫描，计算L3椎水平皮下脂肪组织（SAT）和内脏脂肪组织（VAT）体积、SAT和VAT SUV（标准化摄取值）平均值、SAT和VAT指数、骨骼肌指数（SMI）和骨骼肌放射密度（SMD）。白蛋白-肌骨病指数（AMG）定义为SMD ×白蛋白。结果：该研究包括73名参与者。SAT和VAT量增加与PFS恶化相关（23.4个月对35.5个月，p: 0.015； 25.4个月对33.3个月，p: 0.114）。然而，在无进展生存期（PFS）的多变量cox回归分析中，SAT体积的增加[HR 4.96；p: 0.038)]和SAT SUV均值[HR 2.99；P: 0.016)]为独立危险因素。结论：应注意的是，在接受核糖环尼治疗的患者中，SAT体积和SAT SUV均值的增加是PFS的独立危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.